<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Para-aortic lymph node recurrence is a rare type of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and no treatment has yet been established </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report on a case of isolated para-aortic lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> from <z:e sem="disease" ids="C1327709" disease_type="Neoplastic Process" abbrv="">rectosigmoid cancer</z:e> that showed complete response to <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy with <z:chebi fb="0" ids="31348">capecitabine</z:chebi>/<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> plus bevacizumab </plain></SENT>
<SENT sid="2" pm="."><plain>A 58-year-old woman underwent high anterior resection for <z:e sem="disease" ids="C1327709" disease_type="Neoplastic Process" abbrv="">rectosigmoid cancer</z:e> in 2009 </plain></SENT>
<SENT sid="3" pm="."><plain>Para-aortic lymph node recurrence occurred in 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>She underwent radiation therapy (50 Gy) and 8 courses of <z:chebi fb="0" ids="31348">capecitabine</z:chebi>/<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> plus bevacizumab </plain></SENT>
<SENT sid="5" pm="."><plain>Abdominal computed tomography and <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography with 18-fluorodeoxyglucose did not reveal any para-aortic lymph node recurrence after <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Hence, this case was interpreted as a complete response </plain></SENT>
<SENT sid="7" pm="."><plain>No recurrence was noted 6 months after the complete response </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">Chemoradiation</z:e> therapy with <z:chebi fb="0" ids="31348">capecitabine</z:chebi>/<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> plus bevacizumab is likely to be effective in treating patients with para-aortic lymph node recurrence </plain></SENT>
</text></document>